Dementia: Recent submissions
Now showing items 1-20 of 33
-
Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial
(2024-03)Introduction: Trials of effectiveness of treatment options for depression in dementia are an important priority. Methods: Randomized controlled trial to assess adapted Problem Adaptation Therapy (PATH) for depression in ... -
Do communication interventions affect the quality-of-life of people with dementia and their families? A systematic review
(2023-04)Speech, language and communication difficulties are prevalent in all dementia subtypes and are likely to considerably impact the quality-of-life of people with dementia and their families. Communication interventions ... -
The impact of social isolation due to the COVID-19 pandemic on patients with dementia and caregivers
(2022-04)Objective: Social distancing to limit COVID-19 transmission has led to extensive lifestyle changes, including for people with dementia (PWD). The aim of this study, therefore, was to assess the impact of lockdown on the ... -
Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model
(2022-02)Donepezil, galantamine, rivastigmine and memantine are potentially effective interventions for cognitive impairment in dementia, but the use of these drugs has not been personalised to individual patients yet. We examined ... -
Identification of Substrate-specific Allosteric Fingerprints in Matrix Metalloprotease-1 on Amyloid-beta Peptide Aggregates and Drug Screening With Single Molecule Insights
(2022-02)Amyloid-beta peptide (Aβ) is the primary component of water-insoluble extracellular plaques, one of the critical hallmarks of Alzheimer's disease (AD). Matrix metalloproteases (MMPs) are broad-spectrum proteases with ... -
Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil
(2022-02)The association between early improvement and subsequent change in cognition is unexamined in antidementia clinical trials. We aimed to examine the consequences of early-response to antidementia medication in Alzheimer's ... -
Patient attitudes towards remote memory clinic assessment
(2021-12)Background: Due to demand on UK memory clinic services, most patients have limited consultant interaction before diagnosis/discharge. Technology offers an opportunity for remote assessment, from telephone/video-based ... -
Neurons derived from individual early Alzheimer’s disease patients reflect clinical vulnerability
(2021-11)Modelling sporadic Alzheimer’s disease (sAD) with patient-derived induced pluripotent stem cells (iPSCs) is challenging yet remains an important step in understanding the disease. Here we report a novel approach of sAD ... -
Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data
(2021-09)Evidence in mouse models has found that the antidepressant trazodone may be protective against neurodegeneration. We therefore aimed to compare cognitive decline of people with dementia taking trazodone with those taking ... -
Ethics of Early Intervention in Alzheimer’s Disease
(2021-03)Alzheimer’s disease (AD) research, treatment, and prevention focus increasingly on developing personalized interventions based on personal genetic, biological, phenotypic data, for early intervention (EI) to limit harm. ... -
Development and Validation of a Novel Dementia Risk Score in the UK Biobank Cohort
(2021-03)INTRODUCTION: Current prognostic models of dementia have had limited success in consistently identifying at-risk individuals. We aimed to develop and validate a novel dementia risk score (DRS) using the UK Biobank cohort. ... -
Quantifying the heterogeneity of cognitive functioning in Alzheimer’s disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil
(2021-02)Background. The extent and profiles of heterogeneity in cognitive functioning among participants in clinical trials of antidementia medication are unknown. We aimed to quantify and identify profiles of heterogeneity of ... -
Can dietary supplements maintain cognition in mid- to late-life?
(2020-12)Cognitive health, and prevention of its decline to dementia, has risen in prominence with a corresponding exploration of modifiable risk factors to prevent a decline in cognitive health with age. This commentary discusses ... -
Valproate in dementia: time to move on? Commentary on…Cochrane Corner
(2019-02)Baillon et al ’s Cochrane review included 430 participants with agitation in dementia from five randomised controlled trials. Overall, the reviewers found that valproate was no better than placebo for the treatment of ... -
Quantification of allosteric communications in matrix metalloprotease-1 on alpha-synuclein aggregates and substratedependent virtual screening
(2021-01)Alpha-synuclein (aSyn) has implications in pathological protein aggregations observed in neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. There are currently no approved prevention and cure ... -
Incidence of neurodegenerative and cerebrovascular diseases associated with antihypertensive drug classes
(2021-01)Antihypertensive drugs (AHTs) are associated with lowered risks of neurodegenerative diseases and stroke. However, the relative risks associated with different AHT classes are unclear. Using an electronic health record ... -
The impact of assistive technology on burden and psychological well-being in informal caregivers of people with dementia (ATTILA Study)
(2020-09)Introduction: Assistive technology and telecare (ATT) may alleviate psychological burden in informal caregivers of people with dementia. This study assessed the impact of ATT on informal caregivers’ burden and psychological ... -
Vascular Dementia
(2020-04) -
Linking the Mini-Mental State Examination, the Alzheimer’s Disease Assessment Scale–Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil
(2020-10)Background The Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) and the Severe Impairment Battery (SIB) are widely used rating scales to assess cognition in ... -
Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape.
(2020-07)BACKGROUND:Dementia has been described as the greatest global health challenge in the 21st century on account of longevity gains increasing its incidence, escalating health and social care pressures. These pressures highlight ...
